查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864441

抗瘧疾藥市場按藥物類別、給藥途徑、劑型、通路和最終用戶分類－2025年至2032年全球預測

Antimalarial Drugs Market by Drug Class, Route Of Administration, Formulation, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗瘧疾藥市場規模將成長至 28.4 億美元，年複合成長率為 6.10%。

關鍵市場統計數據
基準年 2024 17.6億美元
預計年份：2025年 18.7億美元
預測年份 2032 28.4億美元
複合年成長率 (%) 6.10%

對影響抗瘧疾藥使用和策略決策的當代臨床、政策和供應鏈環境進行了清晰簡潔的概述。

瘧疾仍然是全球面臨的健康挑戰，抗瘧疾藥對於降低疫區的發病率和死亡率至關重要。本執行摘要了目前影響抗瘧療法的科學、監管和商業性趨勢，並重點闡述了臨床實踐、產品可及性和衛生系統準備情況之間的相互作用。近年來，藥物療效、新出現的抗藥性標記以及不斷更新的治療指南等諸多因素交互作用，正在影響臨床決策和籌資策略。

除了臨床療效外，抗瘧藥物的供應模式也受到生產能力、供應鏈完整性和政策獎勵等因素的影響，這些因素決定了瘧疾流行地區的藥物可近性。儘管公私合營和國際捐助機構的計劃持續推動藥物供應，但各國衛生系統在整合新的治療通訊協定和滿足藥物監測要求方面仍面臨挑戰。因此，從臨床醫生和採購負責人到生產者和政策制定者，相關人員必須應對不斷變化的證據基礎和物流限制。本概述旨在為決策者提供一份簡明指南，幫助他們了解當前的抗瘧疾藥市場格局，並優先採取策略行動，以維持治療效果並確保藥物的持續可及性。

不斷發展的抗藥性科學、更新的治療策略以及供應鏈的韌性正在共同重塑抗瘧疾療法的研發、採購和部署。

抗瘧領域正經歷著由科學進步、政策變革和市場力量共同驅動的變革。在科學方面，對抗藥性機制和分子監測的深入了解正在推動治療指南的修訂，並激發人們對新型聯合治療的興趣。同時，診斷技術的進步和綜合病例管理方法的改進正在改變需求模式，促進標靶治療並減少不合理用藥。

從監管和政策角度來看，隨著監測數據的不斷湧現，國家治療政策的快速更新已成為常態，這要求生產商和採購機構必須具備敏捷性。在商業方面，學名藥生產商之間的整合以及與研究機構的策略聯盟正在重塑供應關係和生產力計畫。同時，近期全球供應鏈的中斷使得供應鏈韌性成為重中之重，推動了對區域製造地、緩衝庫存政策和採購多元化的投資。這些變化共同重塑了藥物的研發、採購和部署方式，為致力於維持有效抗瘧療法的相關人員帶來了風險和機會。

貿易政策變化和關稅如何影響抗瘧疾藥籌資策略、供應多元化以及向本地化生產轉型

美國將於2025年開始加徵關稅，這為國際抗瘧疾藥供應體系的採購、生產和成本結構帶來了新的挑戰。關稅壁壘將影響採購決策，並可能加速本地化進程，因為買家和製造商都在尋求關稅效率更高的供應鏈和本地化生產。為此，一些製造商正在考慮轉移生產或簽訂長期契約，以將關稅的影響內部化，從而保護脆弱市場的價格穩定。

醫療保健採購方和國家計畫不得不重新評估競標規範和供應商多元化，以減輕潛在的干擾。此外，關稅相關的波動凸顯了區域製造地以及國內灌裝和包裝能力的戰略重要性，這些能力可以降低受國際貿易緊張局勢影響的風險。同時，捐助機構和多邊合作夥伴不得不調整資金籌措模式，以應對成本動態的變化，並優先考慮促進永續獲取醫療服務和永續本地能力建設的干涉措施。整體而言，關稅促使人們重新評估供應鏈策略，並凸顯了能夠吸收政策衝擊的靈活採購方式的優勢。

基於對驅動需求和策略差異化因素的詳細分析，包括治療領域、給藥途徑、劑型、通路和終端用戶環境，得出細分市場洞察。

細分分析所揭示的關鍵差異應體現在產品開發、分銷計劃和臨床實施策略的製定中。從藥物類別來看，市場可分為青蒿素類聯合療法和非青蒿素類療法。前者包括一些特定的複方製劑，例如蒿甲醚-苯芴醇、青蒿琥酯-阿莫地喹、青蒿琥酯-甲氟喹和青蒿素-哌喹；後者包括一些常規藥物，例如Chloroquine、甲氟喹、伯氨喹和奎寧。了解每類藥物的治療定位和抗藥性特徵對於制定藥物選擇標準和臨床指南至關重要。

給藥途徑也是關鍵的區分因素，口服和注射劑型適用於不同的應用情境。口服劑型是門診治療和大規模藥物管理宣傳活動的核心，而注射劑型則是重症瘧疾和住院治療的必需品。製劑形式的選擇（例如注射劑、混懸劑、片劑）會影響生產的複雜性、低溫運輸要求以及患者的依從性。通路，包括醫院藥房、線上藥房和零售藥房，為觸達最終用戶提供了多種途徑，並需要不同的商業性和監管策略。最後，將最終用戶細分——包括門診中心、診所和醫院——可以突出需求集中的領域、不同治療通訊協定環境之間的差異，以及在培訓和供應鏈干預方面投入資金將產生最大影響的領域。

流行病學特徵、監管協調以及關鍵地區的生產能力如何影響抗瘧疾療法的獲取途徑和戰略重點

區域趨勢正深刻影響著美洲、歐洲、中東和非洲以及亞太地區的醫療資源取得、監管方式和供應鏈策略，而這些地區各自具有不同的流行病學特徵和衛生系統能力。在美洲，重點往往在於針對性應對、加強監測以及在局部疫情爆發地區和邊境地區維持供應連續性，並與當地製造商和區域採購機制合作，以確保穩定的供應。

在歐洲、中東和非洲地區，監管協調工作和捐助者支持的計畫與非洲部分地區的高負擔環境相交織，在這些地區，藥物可及性和抗藥性管理仍然是優先事項。對監測基礎設施和能力建設的投資可能產生特別顯著的影響。在全部區域，複雜的流行病學情勢和多重抗藥性患者的出現正在推動治療通訊協定的創新，並加速聯合治療療法的應用。同時，該地區部分地區強大的學名藥生產能力正在影響全球供應流動。這些區域趨勢要求在政策參與、採購設計和本地能力建構方面採取差異化的策略，以適應臨床需求和衛生系統實際情況。

在複雜的全球市場中，決定誰能確保有效抗瘧疾治療的企業策略、夥伴關係和營運實踐至關重要。

透過策略投資、夥伴關係和營運協調，主要企業和機構的行動正在塑造抗瘧疾治療的發展軌跡。藥物研發公司持續投資於下一代化合物和新型給藥平台，而現有非專利生產商則專注於提高生產效率和最佳化成本結構，以滿足流行市場的持續需求。合作模式日益普遍，官民合作關係促進了後期臨床試驗、技術轉移以及生產和品質保證方面的能力建設。

同時，契約製造生產商和特種製劑供應商在推動快速擴大生產規模和實現國內灌裝包裝方面發揮關鍵作用。製藥公司與診斷開發商之間的策略聯盟也在不斷發展，將治療與病例檢測的改進聯繫起來。從商業性角度來看，擁有完善的藥物監測系統、遵守國際品質標準以及靈活的供應鏈能力的公司最能有效支持國家計畫和國際捐助者。整體而言，市場可能會青睞那些在研發創新、可靠的生產能力以及對目標市場營運的深刻理解之間取得平衡的企業。

為加強抗瘧疾藥價值鏈各環節的治療效果、供應鏈韌性、監管完整性和相關利益者合作，提出切實可行的策略建議

產業領導者應採取多管齊下的策略，同時提升臨床療效、增強供應鏈韌性並促進相關人員的合作。首先，增加對抗藥性監測、數據共用和適應性臨床計畫的投入，將有助於維持治療價值並促進政策的及時調整。其次，透過區域製造夥伴關係和提升灌裝包裝能力來實現供應鏈多元化，既能提高對區域需求的應對力，又能降低貿易中斷和關稅帶來的風險。

除了採購和生產之外，各組織還應優先考慮綜合產品管理，將可靠的藥物監測與醫護人員教育結合，以維持藥物的合理使用。與監管機構和多邊捐助方積極合作，有助於使採購框架與公共衛生目標保持一致。最後，實施用於需求預測、庫存視覺化和品質監控的數位化工具，將有助於提升產品生命週期各階段的決策水準。綜上所述，這些努力將建構一種具有韌性的方法，支持有效的治療方案和抗瘧工作的長期永續性。

採用透明的混合調查方法，結合證據綜合、與主要相關利益者的訪談以及嚴格的檢驗，以確保研究結果的可靠性和實際意義。

本執行摘要的研究採用了混合方法，結合嚴謹的二手資料綜合分析和有針對性的原始研究，以確保其有效性和相關性。二手資料包括同行評審的臨床文獻、監管指導文件和公共衛生報告，這些資料均經過嚴格的評估，以確保其方法學品質和實踐適用性。原始研究包括對臨床醫生、採購專業人員、製造企業高管和政策顧問進行結構化訪談，以了解營運觀點和實際限制因素。

為整合不同資訊來源並識別一致模式，我們運用了資料三角測量和交叉檢驗技術。同時，我們也考慮了時間因素和近期政策變化，以確保分析結果反映最新實際情況。在定量資料有限的情況下，我們則運用定性分析來解讀趨勢並得出策略啟示。最後，我們實施了包括專家同儕審查和方法透明化在內的品質保證措施，以增強報告的可信度，並使相關人員對報告的結論和建議充滿信心。

結論表明，協調的監測、區域製造投資和營運靈活性對於維持抗瘧疾治療的有效性至關重要。

總之，目前的抗瘧疾藥市場是一個由科學、監管和物流等諸多因素交織而成的複雜網路，需要採取協調一致、以證據為基礎的因應措施。有針對性地投資於抗藥性監測、適應性政策制定以及本地化生產和供應鏈體系，是維持治療效果和確保公平獲取藥物的關鍵所在。從採購設計到本地分銷，能夠整合臨床洞察力和營運靈活性的相關人員，將更有能力應對新出現的挑戰，並支持永續的疾病控制。

公共、私營和慈善組織必須繼續攜手合作，協調獎勵，共用數據，並在最關鍵的領域加強能力建構。透過促進創新，同時專注於建立具有韌性的供應鏈、提高監管靈活性並妥善管理現有療法，國際社會可以持續推動抗擊瘧疾的工作，保護弱勢群體免受可預防疾病和死亡的侵害。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在偏遠社區，單劑量他非諾喹在根治間日瘧原蟲瘧疾的應用日益廣泛
  • 兒科顆粒狀抗瘧藥製劑可提高撒哈拉以南非洲地區的治療順從性
  • 在亞洲主要市場，非專利青蒿素聯合療法的成長面臨價格壓力和監管漏洞。
  • 增加對下一代三聯抗瘧療法的投資，以對抗東南亞的多重抗藥性瘧原蟲株。
  • 將數位藥物依從性技術與行動醫療平台結合，用於監測農村地區的抗瘧疾治療效果

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依藥物類別分類的抗瘧疾藥市場

  • 青蒿素類聯合療法
    • 蒿甲醚-蒿芴醇
    • 青蒿琥酯/阿莫地喹
    • 青蒿琥酯/甲氟喹
    • 青蒿素-哌喹
  • 非青蒿素療法
    • Chloroquine
    • 甲氟喹
    • 伯氨喹
    • 奎寧

第9章 依給藥途徑分類的抗瘧疾藥市場

  • 注射
  • 口服

第10章 以劑型分類的抗瘧疾藥市場

  • 注射
  • 暫停
  • 藥片

第11章 按通路分類的抗瘧疾藥市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終用戶分類的抗瘧疾藥市場

  • 門診治療中心
  • 診所
  • 醫院

第13章 各地區抗瘧疾藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章抗瘧疾藥市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國抗瘧疾藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis International AG
    • GlaxoSmithKline plc
    • Sanofi SA
    • Cipla Limited
    • Viatris Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Limited
    • Ipca Laboratories Limited
    • Dr. Reddy's Laboratories Limited
    • Bayer Aktiengesellschaft
Product Code: MRR-F97DD5A7DAEF

The Antimalarial Drugs Market is projected to grow by USD 2.84 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.76 billion
Estimated Year [2025] USD 1.87 billion
Forecast Year [2032] USD 2.84 billion
CAGR (%) 6.10%

A clear, concise introduction to the contemporary clinical, policy, and supply chain environment shaping antimalarial drug use and strategic decision-making

Malaria remains a persistent global health challenge, and antimalarial drugs are central to reducing morbidity and mortality in affected populations. This executive summary synthesizes current scientific, regulatory, and commercial dynamics shaping antimalarial therapeutics, emphasizing the intersection of clinical practice, product availability, and health system preparedness. Recent years have witnessed a complex interplay between drug efficacy concerns, emergence of resistance markers, and evolving treatment guidelines, which together influence clinical decision-making and procurement strategies.

Beyond clinical efficacy, the landscape is influenced by manufacturing capacity, supply chain integrity, and policy incentives that determine access in endemic regions. Public-private collaborations and international donor initiatives continue to drive distribution efforts, while national health systems wrestle with integration of new treatment protocols and pharmacovigilance requirements. As a result, stakeholders ranging from clinicians and procurement officers to manufacturers and policymakers must navigate shifting evidence and logistical constraints. This overview provides a concise orientation for decision-makers seeking to understand the contemporary context of antimalarial drugs and to prioritize strategic actions that preserve treatment effectiveness and ensure sustained access.

How evolving resistance science, updated treatment policies, and supply chain resilience are jointly reshaping development, procurement, and deployment of antimalarial therapies

The antimalarial space is undergoing transformative shifts driven by scientific advances, policy change, and market forces. On the scientific front, improved understanding of resistance mechanisms and molecular surveillance has prompted revisions to therapeutic guidance and accelerated interest in novel combination therapies. Concurrently, enhanced diagnostics and integrated case management approaches are altering demand patterns, encouraging targeted treatment and reducing inappropriate drug use.

From a regulatory and policy perspective, rapid updates to national treatment policies have become more common as surveillance data emerges, requiring manufacturers and procurement agencies to be more agile. Commercially, consolidation among generics manufacturers and strategic alliances with research institutions are reshaping supply relationships and capacity planning. Meanwhile, supply chain resilience has risen in priority after recent global disruptions, driving investments in regional manufacturing, buffer stock policies, and diversified sourcing. Taken together, these shifts are redefining how drugs are developed, procured, and deployed, creating both risks and opportunities for stakeholders committed to sustaining effective antimalarial therapy.

Implications of trade policy changes and tariffs on procurement strategies, supplier diversification, and the push toward regional manufacturing for antimalarial supplies

The imposition of tariffs by the United States in 2025 introduced new considerations for procurement, manufacturing, and cost structures within the international antimalarial supply ecosystem. Tariff barriers influence sourcing decisions and may accelerate regionalization efforts as purchasers and manufacturers seek tariff-efficient supply chains and localized production. In response, some manufacturers have evaluated shifting production footprints or negotiating long-term contracts that internalize tariff impacts to protect price stability in vulnerable markets.

Healthcare purchasers and national programs have needed to reassess tender specifications and supplier diversification to mitigate potential disruptions. Moreover, tariff-related changes have reinforced the strategic importance of regional manufacturing hubs and in-country fill-and-finish capabilities, which can reduce exposure to international trade frictions. At the same time, donor agencies and multilateral partners have had to adapt funding models to accommodate altered cost dynamics, prioritizing interventions that preserve access while promoting sustainable local capacity. Overall, tariffs have catalyzed a reevaluation of supply chain strategies and underscored the advantage of flexible procurement approaches that can absorb policy-driven shocks.

Detailed segmentation insights highlighting therapeutic classes, administration routes, formulations, distribution channels, and end-user settings that drive differentiated demand and strategy

Segmentation analysis reveals critical nuances that should inform product development, distribution planning, and clinical adoption strategies. When considering drug class, the market is partitioned between artemisinin-based combination therapies and non-artemisinin therapies, with the former encompassing specific combinations such as artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine, and dihydroartemisinin-piperaquine, and the latter including classic agents like chloroquine, mefloquine, primaquine, and quinine; understanding therapeutic niches and resistance profiles across those classes is essential for formulary decisions and clinical guidelines.

Route of administration is another differentiator, with oral and injectable modalities presenting distinct use cases: oral formulations are central to outpatient management and mass drug administration campaigns, whereas injectables are critical for severe malaria and inpatient care. Formulation considerations-whether injectables, suspensions, or tablets-affect manufacturing complexity, cold chain needs, and adherence outcomes. Distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, create divergent pathways to end users and require tailored commercial and regulatory approaches. Finally, end user segmentation across ambulatory care centers, clinics, and hospitals highlights where demand concentrates, how treatment protocols vary by setting, and where investments in training and supply chain interventions will have the greatest impact.

How regional epidemiology, regulatory harmonization, and manufacturing capacity across major global regions shape access pathways and strategic priorities for antimalarial therapies

Regional dynamics deeply influence access, regulatory approaches, and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct epidemiological profiles and health system capacities. In the Americas, the focus often lies on targeted control measures, surveillance strengthening, and maintaining supply continuity for localized outbreaks and border areas; partnership with local manufacturers and regional procurement mechanisms plays a role in ensuring steady availability.

In Europe, the Middle East & Africa, regulatory harmonization efforts and donor-supported programs intersect with high-burden settings in parts of Africa, where access and resistance management remain priorities; investments in surveillance infrastructure and capacity building are particularly impactful. Across Asia-Pacific, complex epidemiology and pockets of multidrug resistance have driven innovation in treatment protocols and accelerated adoption of combination therapies, while robust generic manufacturing in parts of the region affects global supply flows. Collectively, these regional patterns necessitate differentiated strategies for policy engagement, procurement design, and local capacity strengthening to match clinical needs and health system realities.

Corporate strategies, partnerships, and operational practices that are determining who can reliably deliver effective antimalarial solutions in complex global markets

Key corporate and institutional behaviors are shaping the trajectory of antimalarial therapeutics through strategic investments, partnerships, and operational adjustments. Innovator companies continue to invest in next-generation compounds and novel delivery platforms, while established generic manufacturers focus on scaling production efficiency and improving cost structures to meet sustained demand in endemic markets. Collaborative models are increasingly common, with public-private partnerships facilitating late-stage clinical studies, technology transfer, and capacity building in manufacturing and quality assurance.

At the same time, contract manufacturers and specialty formulation providers play a vital role in enabling rapid scale-up and in-country fill-and-finish operations. Strategic alliances between pharmaceutical firms and diagnostic developers are also emerging to align treatment with improved case detection. From a commercial perspective, companies that combine robust pharmacovigilance, compliance with international quality standards, and responsive supply chain capabilities are best positioned to support national programs and international donors. Overall, the market rewards organizations that balance R&D innovation with reliable manufacturing and deep operational understanding of endemic markets.

Actionable strategic recommendations for strengthening therapeutic efficacy, supply chain resilience, regulatory alignment, and stakeholder collaboration across the antimalarial value chain

Industry leaders should adopt a multi-pronged strategy that concurrently advances clinical efficacy, supply resilience, and stakeholder collaboration. First, investment in resistance surveillance, data sharing, and adaptive clinical programs will preserve therapeutic value and inform timely policy adaptations. Second, diversifying supply chains through regional manufacturing partnerships and strengthened fill-and-finish capabilities will reduce exposure to trade disruptions and tariffs while improving responsiveness to localized demand.

Beyond procurement and manufacturing, organizations should prioritize integrated product stewardship, coupling reliable pharmacovigilance with provider education to sustain appropriate use. Engaging proactively with regulatory bodies and multilateral donors enables alignment of procurement frameworks with public health goals. Finally, adopting digital tools for demand forecasting, inventory visibility, and quality monitoring enhances decision-making across the product lifecycle. Taken together, these actions create a resilient approach that supports effective treatment delivery and long-term viability of antimalarial interventions.

A transparent mixed-methods research approach combining evidence synthesis, primary stakeholder interviews, and rigorous validation to ensure credible insights and practical relevance

The research underpinning this executive summary deployed a mixed-methods approach combining rigorous secondary evidence synthesis with targeted primary inquiry to ensure validity and relevance. Secondary inputs included peer-reviewed clinical literature, regulatory guidance documents, and public health reports that were critically appraised for methodological quality and applicability to practice. Primary research involved structured interviews with clinicians, procurement specialists, manufacturing executives, and policy advisors to capture operational perspectives and real-world constraints.

Data triangulation and cross-validation techniques were applied to reconcile divergent sources and to identify consistent patterns. Attention was paid to temporal factors and recent policy changes to ensure the analysis reflects the most current realities. Where quantitative data were limited, qualitative insights were used to contextualize trends and infer strategic implications. Finally, quality assurance measures, including expert peer review and methodological transparency, were implemented to enhance credibility and to provide stakeholders with confidence in the report's findings and recommendations.

Concluding insights emphasizing the imperative of coordinated surveillance, regional manufacturing investments, and operational agility to sustain antimalarial treatment effectiveness

In conclusion, the antimalarial drugs landscape is defined by a confluence of scientific, regulatory, and logistical dynamics that require coordinated, evidence-driven responses. Resistance surveillance, adaptive policy-making, and targeted investments in regional manufacturing and supply chain systems are central to preserving treatment effectiveness and ensuring equitable access. Stakeholders who integrate clinical intelligence with operational agility - from procurement design to on-the-ground distribution - will be better positioned to respond to emerging challenges and to support sustainable disease control efforts.

Moving forward, the emphasis should remain on collaboration across public, private, and philanthropic actors to align incentives, share data, and build capacity where it matters most. By focusing on resilient supply chains, responsive regulatory engagement, and stewardship of existing therapeutics while fostering innovation, the global community can sustain progress against malaria and protect vulnerable populations from preventable illness and death.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of single-dose tafenoquine for radical cure of Plasmodium vivax malaria in remote communities
  • 5.2. Emergence of pediatric-friendly antimalarial granule formulations improving treatment adherence in sub-Saharan Africa
  • 5.3. Growth of generic artemisinin combination therapies facing pricing pressure and regulatory variations across key Asian markets
  • 5.4. Rising investments in next-generation triple combination antimalarial regimens to combat multi-drug resistant strains in Southeast Asia
  • 5.5. Integration of digital adherence technologies and mobile health platforms to monitor antimalarial treatment outcomes in rural zones

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimalarial Drugs Market, by Drug Class

  • 8.1. Artemisinin Based Combination Therapy
    • 8.1.1. Artemether Lumefantrine
    • 8.1.2. Artesunate Amodiaquine
    • 8.1.3. Artesunate Mefloquine
    • 8.1.4. Dihydroartemisinin Piperaquine
  • 8.2. Non Artemisinin Therapies
    • 8.2.1. Chloroquine
    • 8.2.2. Mefloquine
    • 8.2.3. Primaquine
    • 8.2.4. Quinine

9. Antimalarial Drugs Market, by Route Of Administration

  • 9.1. Injectable
  • 9.2. Oral

10. Antimalarial Drugs Market, by Formulation

  • 10.1. Injectables
  • 10.2. Suspensions
  • 10.3. Tablets

11. Antimalarial Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Antimalarial Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Hospitals

13. Antimalarial Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimalarial Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimalarial Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis International AG
    • 16.3.2. GlaxoSmithKline plc
    • 16.3.3. Sanofi S.A.
    • 16.3.4. Cipla Limited
    • 16.3.5. Viatris Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Sun Pharmaceutical Industries Limited
    • 16.3.8. Ipca Laboratories Limited
    • 16.3.9. Dr. Reddy's Laboratories Limited
    • 16.3.10. Bayer Aktiengesellschaft

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIMALARIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIMALARIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMALARIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMETHER LUMEFANTRINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE AMODIAQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ARTESUNATE MEFLOQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DIHYDROARTEMISININ PIPERAQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CHLOROQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY MEFLOQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY PRIMAQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY QUININE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ANTIMALARIAL DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 304. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC ANTIMALARIAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ARTEMISININ BASED COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY NON ARTEMISININ THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION ANTIMALARIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)

TABL